# This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

> **NCT07162571** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology** · enrollment: 17 (estimated)

## Conditions studied

- Acute Lymphobkastic Leukemia
- B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD19/22 CAR-T cells

## Key facts

- **NCT ID:** NCT07162571
- **Lead sponsor:** Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2030-12
- **Final completion:** 2031-12
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07162571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07162571, "This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07162571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*